Alternative medicines to prevent graft-versus-host disease after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of three medicines (sirolimus, ruxolitinib, and mycophenolate mofetil) to prevent graft-versus-host disease (a common complication after a stem cell transplant) in people who cannot take standard anti-rejection drugs. The goal is to find a safer alternative that still protects you from this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like leukemia or myelodysplastic syndrome) or a non-cancer blood disorder (like severe aplastic anemia).
- This is your first transplant using a half-matched family donor (called haploidentical).
- You had kidney problems, high blood pressure, or nerve damage from standard anti-rejection drugs (like tacrolimus or cyclosporine), so you can't take them.
- You do not have an active infection or graft-versus-host disease at the time of the study start.
- Your liver and heart are working well enough (no severe liver injury or heart failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.